Pluribus Labs’s DexCom DXCM Stock Holding History

Pluribus Labs’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$373K	Buy	4,998 +2,782	+126%	+$254K	0.68%	41
2022 Q1	$283K	Buy	+2,216	New	+$242K	1.12%	28

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pluribus Labs's DXCM Position: Q2 2022 in Review

Pluribus Labs increased its DexCom (DXCM) stake by 126% in Q2 2022, buying an estimated $254K and bringing the position to 4,998 shares worth $373K. The position accounts for 0.68% of the portfolio, ranked #41.

Pluribus Labs first reported a position in DXCM in Q1 2022 and has held it in 2 quarters since. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Pluribus Labs held 4,998 shares of DexCom worth $373K as of Q2 2022.
Pluribus Labs bought 2,782 DexCom shares in Q2 2022, an estimated $254K.
DexCom made up 0.68% of Pluribus Labs's portfolio in Q2 2022, its #41 holding.
Pluribus Labs first reported a position in DexCom in Q1 2022 and has held it in 2 quarters since.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.